![Michael Culler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Culler
Directeur Technique/Scientifique/R&D chez Amolyt Pharma SAS
Provenance du réseau au premier degré de Michael Culler
Entité | Type d'entité | Industrie | |
---|---|---|---|
Amolyt Pharma SAS
![]() Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Michael Culler via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Urovant Sciences, Inc.
![]() Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Millendo Therapeutics US, Inc.
![]() Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Egle Therapeutics SAS
![]() Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SIENNA BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ODDO BHF SE
![]() ODDO BHF SE Major BanksFinance ODDO BHF SE provides banking and financial services. It specializes in private banking, asset management, as well as corporate and investment banking. The company was founded in 1854 and is headquartered in Frankfurt, Germany. | Major Banks | Chief Executive Officer | |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
SENSORION | Pharmaceuticals: Major | Director/Board Member | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Natixis SA (Broker)
![]() Natixis SA (Broker) Investment Banks/BrokersFinance Natixis SA (Broker) is the securities brokerage division of Natixis SA (EPA: KN), a corporate and investment bank headquartered in Paris, France. They are ultimately owned by BCPE SA. The firm provides full spectrum of broking services to various investors. | Investment Banks/Brokers | Analyst-Equity | |
Bryan, Garnier & Co Ltd. (France) | Investment Banks/Brokers | Director of Research - Equity | |
ACCURAY INCORPORATED | Medical Specialties | Director/Board Member | |
Aatru Medical LLC
![]() Aatru Medical LLC Medical SpecialtiesHealth Technology Aatru Medical LLC provides wound and damaged skin treatment. The company was incorporated in 2017 and is headquartered in Cleveland, OH. | Medical Specialties | Director/Board Member | |
Phase4 Partners Ltd.
![]() Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Investment Committee Member | |
France Biotech Association
![]() France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Miscellaneous Commercial Services | Director/Board Member | |
NeuroSigma, Inc.
![]() NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Medical Specialties | Director/Board Member | |
Loyola Marymount University | College/University | Director/Board Member | |
Pepperdine University | College/University | Masters Business Admin | |
Allergan Foundation | President | ||
Vicept Therapeutics, Inc.
![]() Vicept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Treasurer | |
ALLERGAN, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Orano Med SAS
![]() Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Biotechnology | Director/Board Member | |
Argobio SAS
![]() Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research. | Miscellaneous Commercial Services | President | |
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member | |
Horama SA
![]() Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Kurma Biofund FCPR
![]() Kurma Biofund FCPR Investment ManagersFinance Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million. | Investment Managers | Corporate Officer/Principal | |
Insead Business School | College/University | Masters Business Admin | |
Mainstay Medical Holdings Plc
![]() Mainstay Medical Holdings Plc Financial ConglomeratesFinance Mainstay Medical Holdings Plc is a medical device company, which focuses on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain. The company was founded in 2020 and is headquartered in Dublin, Ireland. | Financial Conglomerates | Director/Board Member | |
MAINSTAY MEDICAL INTERNATIONAL | Medical Specialties | Director/Board Member | |
Meiogenix SAS
![]() Meiogenix SAS BiotechnologyHealth Technology Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
Leo Pharma, Inc.
![]() Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Drugstore Chains | Director/Board Member | |
Epics Therapeutics SA
![]() Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Kuste Biopharma SAS
![]() Kuste Biopharma SAS Pharmaceuticals: MajorHealth Technology Kuste Biopharma SAS engages in the development of therapies for unmet medical inflammatory. The company was founded in 2019 and is headquartered in Lyon, France. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
PHARNEXT SCA | Biotechnology | Chairman | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
GALAPAGOS NV | Biotechnology | Director/Board Member | |
Janssen Pharmaceuticals, Inc.
![]() Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The Swedish-American Chamber of Commerce, Inc.
![]() The Swedish-American Chamber of Commerce, Inc. Miscellaneous Commercial ServicesCommercial Services The Swedish-American Chamber of Commerce, Inc. is a business organization that provides contacts, partners, and business services to help businesses succeed in the United States. The non-profit company is based in New York, NY, with its office located at 900 3rd Avenue, 29th floor. The chamber offers memberships, marketing opportunities, and events and programming, including the largest transatlantic meet up for female leaders, entrepreneurs, and investors. With over 70 events and three large conferences arranged every year, the chamber's calendar most likely includes the right events for all business needs. | Miscellaneous Commercial Services | Director/Board Member | |
University of Gothenburg | College/University | Doctorate Degree | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
IXALTIS SAS
![]() IXALTIS SAS Pharmaceuticals: MajorHealth Technology IXALTIS SAS develops therapeutics to treat genitourinary tract disorders with unsatisfied medical need. The company was founded by Christian Chavy, Philippe Lluel, Roberto Gradnik, Stefano Palea, Pascal Rischmann, and Xavier Gamé in 2012 and is headquartered in Archamps, France. | Pharmaceuticals: Major | Corporate Officer/Principal | |
FOLLICUM AB (PUBL) | Pharmaceuticals: Major | Director/Board Member | |
EQT Life Sciences Group BV
![]() EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Life Sciences Acceleration Alliance eV | Director/Board Member | ||
Evommune, Inc.
![]() Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Columbia Business School | College/University | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 20 |
France | 19 |
Suède | 5 |
Allemagne | 3 |
Belgique | 3 |
Sectorielle
Health Technology | 28 |
Finance | 10 |
Commercial Services | 7 |
Consumer Services | 6 |
Retail Trade | 2 |
Opérationnelle
Director/Board Member | 75 |
Independent Dir/Board Member | 15 |
Corporate Officer/Principal | 12 |
Chief Executive Officer | 10 |
Chairman | 10 |
Relations les plus connectées
- Bourse
- Insiders
- Michael Culler
- Connexions Sociétés